I've been digging Albumin binding mechanism. The nano particle deliver mechanism isn't unheard off. There have been many drugs successfully employed such delivery method. I'd say there are definitely interested parties especially a drug that FDA agrees to a path way and granting rolling NDA, approval chances are good. Plus Aldoxrubicin have been listed as new STS treatment method but information is not up to date with current development. That much is well known public information. I don't think many people will disagree on that.
So what's in store for Cytrx is all on management.
Market Data 
Markets 
AI
